Professional Resources

Fresenius Medical Care provides resources including downloadable tools that can be used in your practice. You can also request a visit from a representative to get more information and samples of Velphoro.

Velphoro Sample Request Form

Fill out this form to receive free samples of Velphoro for your office.

Velphoro Savings Card

Distribute these cards to your patients for whom you prescribe Velphoro to help them save money on their monthly prescriptions.

Velphoro Access Solutions/Patient Assistance Program Application

Fill out one form to begin the access process for patients, regardless of their coverage type.

Velphoro Prescribing Information

Full Prescribing Information for Velphoro including patient counseling information.

2015 Published Registrational Study Results

Floege J, Covic AC, Ketteler M, et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.

2014 Published Registrational Study Results (PubMed)

Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.

Patient Resources

Velphoro Patient FAQ

Two-page sheet that answers important questions about Velphoro, such as how it works and how it should be taken. (Click here for the Spanish version)

Velphoro Patient Brochure

Brochure containing information for patients on what Velphoro is, how it works, and how to take it. (Click here for the Spanish version)


Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.


  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451